



PRODUCT:

**VYNDAQEL® (tafamidis meglumine)**

COMPANY: Pfizer Inc.

THERAPEUTIC AREA & INDICATION:

For cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM) to reduce cardiovascular mortality and related hospitalizations

---

ABOUT THE PRODUCT

*Stay tuned*